Ovarian Cancer
Conditions
Brief summary
Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status are unknown. Previous study, we analyzed the dynamic immunological changes in peripheral T cells during PARP inhibitor maintenance therapy and found predictive biomarkers. The purpose of this study is to prospectively validate the biomarkers for predicting response to PAPR inhibitors in ovarian cancer. We collect serial blood samples (before initiation of therapy and after 1, 3, and 6 months) in ovarian cancer patients who receive PARP inhibitor and analyze immunological characteristics of peripheral CD8 and regulatory T cells. Through assessment of the baseline properties and dynamic changes in T cells, we aim to validate the predictive biomarker and develope promising novel targets to enhancing survival outcomes of high-risk patients.
Interventions
None listed
Sponsors
Yonsei University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1\. Pathological diagnosis of epithelial ovarian cancer, 2. Presence of germline or somatic BRCA mutational status result, 3. Advanced or recurrent ovarian cancer patients who responded to their most recent platinum-based chemotherapy and plan to start PARPi (olaparib or niraparib) maintenance therapy.
Exclusion criteria
1\. Patients who refuse to participate, 2. Patients having difficulty understanding the protocol due to language barrier
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validation of biomarkers for predicting response to PAPR inhibitor | The primary endpont will be accessed 12 months after last patient registration. | Investigators will utilize baseline peripherap blood mononuclear cells (PBMCs) to validate predictive biomarkers to PARP inhibitor. Response to PAPR inhibitor was defined by BRCA1/2 status and duration of PAPR inhibitor treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identify dynamic immunological changes during PAPR inhibitor therapy | Immunological changes (Time Frame: 6 months | Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy. |
| Identify promising novel targets to enhance survivla outcomes of high-risk pateints in PAPR inhibitor therapy. | Identify promising novel targets (Time Frame: 12 months) | Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy. |
Countries
South Korea
Contacts
Primary ContactJung-Yun Lee
Outcome results
None listed